Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk factors in rheumatoid arthritis
A paper published in Clinical Rheumatology from the research group of our Scientific Officer Manuel Castro Cabezas and Chief Scientific Officer Rick Grobbee indicates that patients with rheumatoid arthritis with high liver fibrosis scores are likely to have a higher risk of cardiovascular events. Incorporating fibrosis measurements into routine clinical care for rheumatoid arthritis patients could identify individuals with highest risk and enable risk management strategies.
Read more here or reach out to our experts if you have any questions.
Related
Case Study: Accelerating Performance in a Phase III CVOT Rescue Program for a Mid-Size Biotech
Rescuing a Stalled Cardiovascular Outcomes Trial Through Targeted Operational Intervention When a Phase III cardiovascular outcomes trial (CVOT) faced significant enrollment delays and timeline risk, Julius Clinical was engaged to support and acc...
Case Study: Supporting Global Delivery of a Phase III Cardiovascular Outcomes Trial for a Global Top-10 Pharmaceutical Company
Executing a Complex Phase III Diabetes Cardiovascular Outcomes Trial in a High-Risk Population Cardiovascular outcomes trials (CVOTs) in type 2 diabetes present a unique combination of clinical, operational, and regulatory complexity, particularl...
Julius Clinical Expands CNS and Cardiometabolic Capabilities with Post-Merger Growth and New Operations in Spain and Germany
Zeist, The Netherlands – 14.05.2025 – Julius Clinical, a leading clinical Contract Research Organization (CRO) with deep therapeutic expertise in CNS and Cardiometabolic indications, today announced continued growth in bookings in these key th...